Last reviewed · How we verify
NCT04611386
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
trial testing computerized tomography in Contrast Agents and Oral Factor Xa Inhibitor in 65 participants. Completed in 1 August 2019.
1 July 2019
Quick facts
| Lead sponsor | Bursa Postgraduate Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 1 January 2019 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- computerized tomography — full drug profile →
Conditions studied
- Contrast Agents and Oral Factor Xa Inhibitor — all drugs for Contrast Agents and Oral Factor Xa Inhibitor →
Sponsor
Bursa Postgraduate Hospital
Who can join
Adults 21 to 80, any sex, with Contrast Agents and Oral Factor Xa Inhibitor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The effect of contrast agents on the anticoagulant properties of oral factor Xa inhibitors.
Cavlan B, Ari S, Ari H, Çamci S, et al · · 2023 · PMID 35296141 · DOI 10.1177/02841851221081474 -
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
TUNCAY B, Ari S, Ari H, CAMCI S, et al · · 2021 · DOI 10.21203/rs.3.rs-647503/v1 -
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
Tuncay B, Arı S, Arı H, Camcı S, et al · · 2021 · DOI 10.22541/au.162522119.98679759/v1
Verify or expand the search:
- PubMed search for NCT04611386
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of computerized tomography
Trials testing the same drug.
- NCT06728150 — Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management o · not yet recruiting
- NCT06616103 — Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB · not yet recruiting
- NCT06869694 — Energy CT in Imaging and Diagnosis of Gastric Cancer · recruiting
- NCT03937193 — Normal Range of Superior Mesenteric Artery in Young Chinese Population and Its Correlation With Retroperitoneal Adipose · completed
- NCT06867172 — Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma · recruiting
Other Bursa Postgraduate Hospital trials
Trials by the same sponsor.
- NCT07129122 — A Novel Technique for Percutaneous Mitral Paravalvular Leak Closure: LBBAP Lead Assisted Ventricular Septal Way · completed
- NCT06878638 — Nitrate - Clopidogrel - Acute Coronary Syndrome · completed
- NCT06951737 — Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients · completed
- NCT05541757 — Rivaroxaban - Percutaneous Coronary Intervention · completed
- NCT04507282 — Eosinophil and Anticoagulation in COVID-19 Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611386 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bursa Postgraduate Hospital
- Last refreshed: 2 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611386.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing